ストックスクリーナーアプリを入手
1.02
0.99%
0.01
前日終値:
$1.01
開ける：
$1
24時間の取引高:
48,813
Relative Volume:
0.38
時価総額：
$22.21M
収益：
-
当期純損益:
$-22.29M
株価収益率:
-0.8644
EPS:
-1.18
ネットキャッシュフロー:
$-17.12M
1週間 パフォーマンス:
-2.39%
1か月 パフォーマンス:
-0.97%
6か月 パフォーマンス:
-37.80%
1年 パフォーマンス:
-73.09%
1日の値動き範囲:
$1.00
$1.04
1週間の範囲:
$1.00
$1.1329
52週間の値動き範囲:
$0.8101
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
ENLV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.02 | 22.21M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-03-02 | 繰り返されました | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd (ENLV) 最新ニュース
Enlivex Therapeutics (ENLV) to Release Quarterly Earnings on Friday - Defense World
HC Wainwright Has Negative Estimate for ENLV FY2025 Earnings - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Given New $7.00 Price Target at HC Wainwright - Defense World
Enlivex stock price target raised to $7 at H.C. Wainwright By Investing.com - Investing.com South Africa
Enlivex stock price target raised to $7 at H.C. Wainwright - Investing.com India
Enlivex Secures Chinese Patent Allowance for Osteoarthritis Treatment - TipRanks
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis - The Manila Times
Enlivex Therapeutics Secures Patent Allowance in China for Allocetra™ as Treatment for Osteoarthritis - Nasdaq
Breakthrough: Enlivex's Arthritis Drug Cuts Pain by 47%, Secures Major China Patent Win - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Update - Defense World
IOBT To Report Melanoma Trial Data In Q3, NPCE Eyes 15-20% Revenue Growth For 2025, DXR On Watch - RTTNews
Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis - The Manila Times
Enlivex Reports Promising Interim Results in Osteoarthritis Trial - TipRanks
Enlivex Therapeutics Announces Investor Webinar To Discuss Positive Interim Data From Phase I/Ii Allocetra(TM) Trial In Knee Osteoarthritis - Marketscreener.com
Enlivex Therapeutics Ltd. Hosts Investor Webinar to Discuss Positive Interim Data from Allocetra™ Osteoarthritis Trial - Nasdaq
Can Enlivex's Allocetra Transform Osteoarthritis Treatment? 47% Pain Reduction Reported - StockTitan
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at D. Boral Capital - Defense World
Enlivex Announces Positive Interim Data From Early Stage Trial For Osteoarthritis Treatment - Nasdaq
Enlivex Reports Promising Interim Results in Knee Osteoarthritis Trial - TipRanks
Enlivex Announces Positive Interim DataStatistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex Therapeutics Reports Positive Interim Results in Phase I/II Trial of Allocetra™ for Knee Osteoarthritis - Nasdaq
Can Enlivex's Osteoarthritis Treatment Disrupt a Multi-Billion Dollar Market? 6-Month Data Impresses - StockTitan
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate - Simply Wall St
Enlivex Advances Immunotherapy with Japanese Patent for Osteoarthritis Treatment - PUNE.NEWS
Enlivex Therapeutics (NASDAQ:ENLV) Hails Positive Trial Results for Allocetra Treatment of Knee Osteoarthritis - Markets Insider
Enlivex Therapeutics Starts Phase II Allocetra Trail to Treat Knee Osteoarthritis - Markets Insider
Enlivex Wins Key Patent in Japan for Osteoarthritis Treatment - Markets Insider
Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial - Markets Insider
Enlivex Issues Urgent Statement on Fraudulent News Dissemination - The Manila Times
Enlivex Therapeutics Denies False Report of Trading Suspension and Reaffirms Business Operations - Nasdaq
Enlivex Takes Legal Action Against Market Manipulation as Stock Trading Continues Uninterrupted - StockTitan
CollPlant Biotechnologies Provides a Corporate Update - Quantisnow
Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion - TipRanks
RedChip Announces Webinar to Teach Investors How to Use RedChat, a Revolutionary AI Chatbot for Small-Cap Stock Analysis - Yahoo Finance
Enlivex Therapeutics’ (ENLV) “Buy” Rating Reiterated at D. Boral Capital - Defense World
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy? - Defense World
Sepsis Market Forecasted to Surge in Coming Years, 2024-2034 - openPR
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis - ACCESS Newswire
Enlivex Therapeutics and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - ACCESS Newswire
Head-To-Head Analysis: Bright Minds Biosciences (NASDAQ:DRUG) versus Enlivex Therapeutics (NASDAQ:ENLV) - Defense World
Enlivex CEO to Showcase Breakthrough Allocetra Cell Therapy on Bloomberg TV Special Feature - StockTitan
Hoth’s phase IIa derma data in cancer patients propels its stock - BioWorld Online
Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 6% – Still a Buy? - Defense World
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance
Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Trump's crypto advocacy steers businesses away from traditional treasury assets - Yahoo Canada Finance
Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan
Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks
Enlivex Therapeutics Ltd (ENLV) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):